Evidence map›Paper›PMID 38238510›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2024

The antihypertensive action of C-phycocyanin is related to the prevention of angiotensin II-caused vascular dysfunction in chronic kidney disease.

Jorge A Tapia-Martínez, David Centurión, Margarita Franco-Colin, Araceli Sánchez-López, Jesus H Beltran-Ornelas, Diana L Silva-Velasco, Plácido Rojas Franco, Vanessa Blas-Valdivia, Edgar Cano-Europa

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jorge A Tapia-MartínezDepartamento de Farmacobiología. Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Calzada de los Tenorios 235, Col. Granjas Coapa, 14330, Ciudad de Mexico, México.
David CenturiónDepartamento de Farmacobiología. Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Calzada de los Tenorios 235, Col. Granjas Coapa, 14330, Ciudad de Mexico, México.
Margarita Franco-ColinLaboratorio de Metabolismo I, Departamento Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Av. Wilfrido Massieu 399, Col. Nueva Industrial Vallejo, 07738, Ciudad de México, México.
Araceli Sánchez-LópezDepartamento de Farmacobiología. Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Calzada de los Tenorios 235, Col. Granjas Coapa, 14330, Ciudad de Mexico, México.
Jesus H Beltran-OrnelasDepartamento de Farmacobiología. Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Calzada de los Tenorios 235, Col. Granjas Coapa, 14330, Ciudad de Mexico, México.
Diana L Silva-VelascoDepartamento de Farmacobiología. Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Calzada de los Tenorios 235, Col. Granjas Coapa, 14330, Ciudad de Mexico, México.
Plácido Rojas FrancoLaboratorio de Metabolismo I, Departamento Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Av. Wilfrido Massieu 399, Col. Nueva Industrial Vallejo, 07738, Ciudad de México, México.
Vanessa Blas-ValdiviaLaboratorio de Neurobiología. Laboratorio de Metabolismo I, Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Av. Wilfrido Massieu 399, Nueva Industrial Vallejo, 07738. Ciudad de México, CDMX, Instituto Politécnico Nacional, Ciudad de Mexico, Mexico. vblasv@ipn.mx.
Edgar Cano-EuropaLaboratorio de Metabolismo I, Departamento Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Av. Wilfrido Massieu 399, Col. Nueva Industrial Vallejo, 07738, Ciudad de México, México. ecanoe@ipn.mx.
Instituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-phycocyanin (CPC) is a photosynthetic protein found in Arthrospira maxima with a nephroprotective and antihypertensive activity that can prevent the development of hemodynamic alterations caused by chronic kidney disease (CKD). However, the complete nutraceutical activities are still unknown. This study aims to determine if the antihypertensive effect of CPC is associated with preventing the impairment of hemodynamic variables through delaying vascular dysfunction. Twenty-four normotensive male Wistar rats were divided into four groups: (1) sham + 4 mL/kg/d vehicle (100 mM of phosphate buffer, PBS) administered by oral gavage (og), (2) sham + 100 mg/kg/d og of CPC, (3) CKD induced by 5/6 nephrectomy (CKD) + vehicle, (4) CKD + CPC. One week after surgery, the CPC treatment began and was administrated daily for four weeks. At the end treatment, animals were euthanized, and their thoracic aorta was used to determine the vascular function and expression of AT1, AT2, and Mas receptors. CKD-induced systemic arterial hypertension (SAH) and vascular dysfunction by reducing the vasorelaxant response of angiotensin 1-7 and increasing the contractile response to angiotensin II. Also, CKD increased the expression of the AT1 and AT2 receptors and reduced the Mas receptor expression. Remarkably, the treatment with CPC prevented SAH, renal function impairment, and vascular dysfunction in the angiotensin system. In conclusion, the antihypertensive activity of CPC is associated with avoiding changes in the expression of AT1, AT2, and Mas receptors, preventing vascular dysfunction development and SAH in rats with CKD.

Indexed as

HypertensionRenal Insufficiency, ChronicAngiotensin IIAnimalsAntihypertensive AgentsMalePhycocyaninRatsRats, WistarReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Receptors, AngiotensinAngiotensin IIAntihypertensive AgentsPhycocyaninReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Receptors, AngiotensinAngiotensin 1–7Angiotensin IIAntihypertensiveChronic kidney diseaseC-phycocyaninVascular dysfunction

Identifiers

PMID38238510
OpenAlexW4390964656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.